Journal of Steroid Biochemistry, 1972, Vol. 3, pp. 761–764. Pergamon Press. Printed in Great Britain

ERRATA

Amendments to IUPAC-IUB 1967 Revised tentative Rules for Steroid Nomenclature: *J. steroid Biochem.* 1 (1970) 143–175.

p. 143, line 8: for hexa-cyclic, read hexacyclic.

p. 143, line 15: for Hetero, read Heterocyclic.

p. 143, bottom: add the following paragraph: The Commissions are greatly indebted to R. S. Cahn, formerly Titular Member and later Associate Member of the Commission on the Nomenclature of Organic Chemistry, who has taken a great part in the work on Nomenclature of Steroids.

p. 144, paragraph 4 (last 3 lines): delete Decision on . . . dealing with them.

p. 145, paragraph 2, lines 4 and 5: delete or order of complexity. For Rule* C-15.11(e), read Nomenclature of Organic Chemistry. Section C. New edition in press.

p. 145, line 4 up: delete or is unspecified.

p. 147, rule 1.5: complete Notes by: If two carbon chains are attached at position 17, see notes (d) and (e) to Rule 2S-2.3.

p. 151, rule 2.3(c) formula 31, read 19(10 → 9β)-*abeo*-5α,10α-Lanostane.



(31A)

p. 151, 2.3(c): add to formulae (31A): 5α-Protostane, 4,4,8,14-Tetramethyl-18-nor-5α,8α,9β,13α,14β,17β,20R-cholestane (this is an important biogenetic precursor of tetracyclic triterpenoids and steroids).

p. 151, rule 2.3: add further notes: (d) If a steroid has two carbon chains attached at position 17 and one of them is included in the Table under Rule 2.3, the compound is named as a 17-alkyl derivative of the steroid in the Table carrying that substituent [e.g. 17-methyl-5α-pregnane (31B); 17-propyl-5α, 17α-cholestane (31C)]. (e) If a steroid has two carbon chains attached at position 17, neither of which is included in the Table under Rule 2.3, the compound is named as a 17,17-disubstituted androstane [e.g. 17,17-dimethyl-5α-androstane (31D); 17α-methyl-17β-propyl-5α-androstane (31E)]. Add formulae [31 A. B. C. D. E].



(31B)



(31C)



(31D)



(31E)

p. 155, last line paragraph 1: delete unspecified or.

p. 155, rule 3.3: formula (A) to be amended at C-24 (Fig. 1).



p. 155, rule 3.3: name of (A) to be (24R, 25R)-24-Bromo-5β-spirostan-3β-ol.

p. 156, table: delete (54) and (55) in last column.

p. 156, table and formula (55): for (20R, 22R, 25R), read (20R, 25R).

p. 156, formula (56): replace H_2C at C-13 by H_3C.

p. 157, formulae (56) and (59): The ends of the side-chains in these two formulae should be redrawn, as shown in Fig. 2. This makes the epimerism with (57) and (58) clearer.



p. 160, lines 1 and 2: for 3β,17α,20α, read 3β,17,20α (twice).

p. 160, table: Cortisol, systematic name for 11β,17α,21, read 11β,17,21. Cortisone, systematic name for 17α,21, read 17,21.

p. 160, names under formulae (60–63): for 17(αH) or 17(βH), read 17α(H) or 17β(H).

p. 161, rule 5.2: add Note: The prefix retro, indicating 9β,10α-configuration, is not recommended for systematic nomenclature.

p. 163, rule 5.6: in the systematic name for (74B), the [a] in square brackets should be italicized, not roman.

p. 164, rule 7.1, line 3 up: for an italic letter, read an italic capital letter.

p. 164, footnote: replace second sentence by: they are placed after any prefixes denoting substituents and before any sterochemical prefixes

required by Rule 2S-1.5, or if there are none of the latter, then immediately before the stem name.

p. 166, footnote: for -5α,10(αH)-, read -5α,10α(H)-.

p. 168, (94): for H_3C read CH_2.

pp. 168–169, (95)–(98): the *abeo* names of the compounds (95–98) are to be amended as follows: (95) 5(10→ 1-*abeo*)-1α(H),5α-Androstane, (96) 14(13 → 12-*abeo*)-5β,12β(H)-Chol-13(17)-en-24-oic acid, (97) 14(8 → 9-*abeo*)-5α,9ξ-Cholestane*. [*This configuration at C-9, if known, is assigned by the sequence-rule procedure (for reference, see footnote on p. 143)], (98) 1(10 → 6-*abeo*)-5β,6β(H)-Androstane (an anthrasteroid).

p. 168, footnotes: the names of these compounds, according to Rule 2S-7.4 ("homo-nor" system) are as follows: (95) 9aβ-Methyl-B(9a)-homo-A-nor-5α,10α-estrane, (96) (4R)-4-(17a-Methyl-D-homo-C-nor-18-nor-5β-androst-17-en-17-yl)pentanoic acid, or 17-[(1R)-3-Carboxy-1-methylpropyl-]17a-methyl-D-homo-C-nor-18-nor-5β-androst-17-ene, (97) cannot conveniently be named by the "homo-nor" system, (98) The "homo-nor" system is not appropriate.

p. 170, table cevanine: for 17αH, 13βH, 20R, read 13βH, 17αH, 20R.

p. 173, line 3: for naphtha[2′,3′:2,3]-read naphth[2′,3′:2,3]-

p. 173, paragraph 3, lines 4, 5, 10: for 2′H, read 3′H (three times).

p. 173, paragraph 3, line 10: for -cyclopropa[, read -cycloprop].

D. B. GOWER: Review on: 16-unsaturated C_{19} steroids. *J. steroid Biochem.* **3** (1972) 45.

p. 51, Fig. 2H: the formula should appear:



p. 56, line 16 up: 'of' should be inserted between 'formation' and 'androstadienone'

p. 56, line 5 up: C_{19} should read C_{21}

p. 62, line 8 down: 'this' should be omitted

Fig. 19, facing p. 64: after 6b, ae-α is missing from the legend

p. 66, Table 10; lines 9–11 down: Precursors should read:

pregnenolone
20β-dihydropregnenolone
20α-dihydropregnenolone